Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients
We conclude that resistance to tofacitinib is mediated by the hyperactivation of myeloid cells and we identify IL-10-dependent macrophages as one cellular subset contributing to this resistance.
Authors
- E Ricart (ORCID: https://orcid.org/0000-0003-3354-1594)
- Marisol Veny (ORCID: https://orcid.org/0000-0002-5702-4789)
- Manel Esteller (ORCID: https://orcid.org/0000-0003-4490-6093)
- Maria Carme Masamunt (ORCID: https://orcid.org/0000-0001-8736-1623)
- Severine A.R.A. Vermeire (ORCID: https://orcid.org/0000-0001-9942-3019)
- Elisa Melón-Ardanaz (ORCID: https://orcid.org/0000-0003-1838-5474)
- Bram Verstockt (ORCID: https://orcid.org/0000-0003-3898-7093)
- Azucena Salas (ORCID: https://orcid.org/0000-0003-4572-2907)
- Julián Panés (ORCID: https://orcid.org/0000-0002-4971-6902)
- Berta Caballol (ORCID: https://orcid.org/0000-0002-7921-6730)
- A M Corraliza (ORCID: https://orcid.org/0000-0002-3067-7763)
- Victòria Gudiño (ORCID: https://orcid.org/0000-0003-1663-975X)
- Marta Gallego (ORCID: https://orcid.org/0000-0002-2406-6624)
- Alba Garrido-Trigo
- A Fernández-Clotet (ORCID: https://orcid.org/0000-0001-7513-0764)
- Ángel L. Corbí (ORCID: https://orcid.org/0000-0003-1980-5733)
- Íngrid Ordás (ORCID: https://orcid.org/0000-0001-7632-0340)
- Ángela Sanzo-Machuca (ORCID: https://orcid.org/0000-0003-0457-8830)
- Maria Teresa Rodrigo‐Calvo (ORCID: https://orcid.org/0000-0001-6675-3425)
- À Giner (ORCID: https://orcid.org/0000-0001-8314-1172)
- Marc Buendia
- Lisseth Robbins-Moreno
Institutions
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Centro de Investigaciones Biológicas Margarita Salas (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf076
- Citations
- 7
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 12.72
Funders
- Pfizer
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- KU Leuven
- Ministerio de Ciencia e Innovación
- Universitat de Barcelona
- Universitaire Ziekenhuizen Leuven, KU Leuven